HOME >> MEDICINE >> NEWS
First clinical trial of gene therapy for childhood blindness

The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London). The trial, funded by the Department of Health, is the first of its kind and could have a significant impact on future treatments for eye disease.

The trial involves adults and children who have a condition called Lebers congenital amaurosis (LCA), which is a type of inherited retinal degeneration. This disease causes progressive deterioration in vision, due to an abnormality in a particular gene called RPE65. This defect prevents normal function of the retina, the light-sensitive layer of cells at the back of the eye. This results in severely impaired vision from a very young age and there are currently no effective treatments available.

The new technique that will be used in the trial involves inserting healthy copies of the gene into the cells of the retina to help them to function normally. Restoring the activity in these cells should restore vision. The operation delivers the normal genes to the retina, using a harmless virus or "vector" to carry the gene into the cells. The vector has been manufactured for this trial by Targeted Genetics, Seattle, USA.

Previous work using animal models has demonstrated that this gene therapy can improve and preserve vision. During trials, the vision of dogs with the defect was restored to the extent that they were able to walk through a maze without difficulty; something they could not do before the treatment. As this trial is the first to treat an eye disease using administration of gene therapy vectors to human retinas, the team have carried out extensive pre-clinical testing. The purpose of this trial is to find out how safe and effective the new intervention is in humans.

The team conducting the trial, from UCL Institute of Ophthalmology and Moorfields Eye Hospital, is led by Professor Robin Ali and includes leading eye surge
'"/>

Contact: Ruth Metcalfe
r.metcalfe@ucl.ac.uk
07-990-675-947
University College London
1-May-2007


Page: 1 2

Related medicine news :

1. First of its kind report on how children with brain tumors perform at school
2. First nationwide child health and air pollution study commences
3. First step in developing heart hormone-based pill to control high blood pressure
4. First greenhouse gas animations produced using Envisat SCIAMACHY data
5. First ozone and nitrogen dioxide measurements from MetOp-A
6. First-degree fetal heart block may be reversible
7. 10 outstanding scientists chosen as First Environmental Health Science Fellows
8. First-time mothers at increased risk for postpartum mental disorders
9. Transforming knowledge into economic benefits -- EPSRCs First Knowledge Transfer Challenge Awards
10. First Quantum Grant to fund stem cell repair of damage from stroke
11. First major study of mammalian disorderly proteins

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... November 14, 2019 , ... With Giving Tuesday on Dec. ... businesses and organizations about the benefits of supporting local hospitalized veterans throughout Maryland. ... millions of people to give, collaborate and celebrate generosity before the holidays, and ...
(Date:11/14/2019)... (PRWEB) , ... November 14, ... ... VALIDATE® SP1 linearity and calibration verification kit, specifically targeted for Roche cobas® ... human-serum matrix, evaluates a1-Antitrypsin (ATT), Complement C3 (C3), Complement C4 (C4), Immunoglobulin ...
(Date:11/14/2019)... Va. (PRWEB) , ... November 14, 2019 , ... BioInformatics ... the life science tools market, today announced that 7 companies have been nominated for ... new products in 2019. , Since 2002, the Life Science Industry Awards have recognized ...
(Date:11/14/2019)... , ... November 14, 2019 , ... ... Drug Administration (FDA) has granted acceptance to file status of its application for ... manifestation in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the ...
(Date:11/12/2019)... GREENWOOD, Ind. (PRWEB) , ... November 12, 2019 ... ... acknowledges a select group of individuals/organizations who have truly impacted those diagnosed with ... Crockin received RESOLVE’s prestigious Hope Award for Achievement, presented at the Night of ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... ... November 11, 2019 , ... Windsor ... Compliance and Ethics Week. The Society of Corporate Compliance and Ethics & ... scheduled this year from November 3 through 9, 2019. This is the third ...
(Date:11/11/2019)... ... November 11, 2019 , ... A highly ... R. Keith Jarman adds a new dimension to Advanced Bone and Joint, by ... years of experience, Dr. Jarman is trained in the evaluation and treatment of ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... drug class and have a major impact in the oncology field. While ... need to be overcome. Among these, defining valuable and adapted combination protocols, ...
Breaking Medicine Technology:
Cached News: